



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/649,017	08/27/2003	Bart De Corte	JANS-0035	5916
23377	7590 02/23/2005		EXAMINER	
WOODCOCK WASHBURN LLP			BALASUBRAMANIAN, VENKATARAMAN	
	ONE LIBERTY PLACE, 46TH FLOOR 1650 MARKET STREET		ART UNIT	PAPER NUMBER
PHILADEL	PHIA, PA 19103	, PA 19103		
	·		DATE MAILED: 02/23/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)		
Office Action Summary		10/649,017	DE CORTE ET AL.		
		Examiner	Art Unit		
		Venkataraman Balasubramanian	1624		
Period f	The MAILING DATE of this communication app or Reply	pears on the cover sheet with the c	orrespondence address		
A SF THE - Exte afte - If th - If No - Faili Any	MAILING DATE OF THIS COMMUNICATION. ensions of time may be available under the provisions of 37 CFR 1.13 r SIX (6) MONTHS from the mailing date of this communication. e period for reply specified above is less than thirty (30) days, a reply poperiod for reply is specified above, the maximum statutory period ware to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be tim y within the statutory minimum of thirty (30) days vill apply and will expire SIX (6) MONTHS from . cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).		
Status					
1)⊠	Responsive to communication(s) filed on 22 No	ovember 2004.			
	This action is FINAL . 2b) This action is non-final.				
3)	Since this application is in condition for allowan	nce except for formal matters, pro	secution as to the merits is		
	closed in accordance with the practice under E				
Disposit	ion of Claims				
	Claim(s) 14-20,23 and 24 is/are pending in the	application	•		
7)63	4a) Of the above claim(s) is/are withdraw				
5)□	Claim(s) is/are allowed.	withom consideration.			
·	Claim(s) 14-20,23 and 24 is/are rejected.		•		
	. <u> </u>				
	Claim(s) are subject to restriction and/or	alaction requirement			
		election requirement.			
	ion Papers				
	The specification is objected to by the Examiner				
10)[]	The drawing(s) filed on is/are: a) acce				
	Applicant may not request that any objection to the d				
4.0.	Replacement drawing sheet(s) including the correction				
11)[_]	The oath or declaration is objected to by the Exa	aminer. Note the attached Office	Action or form PTO-152.		
Priority u	ınder 35 U.S.C. § 119				
_	Acknowledgment is made of a claim for foreign p All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priori application from the International Bureau	have been received. have been received in Application ty documents have been received	on No		
* S	See the attached detailed Office action for a list of		i .		
Attachmen	t(s)				
) 🔲 Notic	e of References Cited (PTO-892)	4) Interview Summary (PTO-413)		
) Notic	e of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Dat	e		
Paper	nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date 12/30/04.	5) Notice of Informal Pa	tent Application (PTO-152)		

Application/Control Number: 10/649,017

Art Unit: 1624

DETAILED ACTION

Applicants' response, which included cancellation of claim 21, addition of new claims 23-24 and amendment to claims 14, filed on 11/22/2004, is made of record.

Claims 14-20 and 23-24 are now pending.

In view of applicants' response, all 112 rejections and double patenting rejection of claim21 are obviated. However, the following remains.

Information Disclosure Statement

References cited in the Supplemental Information Disclosure Statement filed on 12/30/2004, are made of record except for Kubunshi Kagaku reference for which no English language abstract provided.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 14 and 16 are rejected under 35 U.S.C. 102(b) as being anticipated by Ashley et al. J. Chem. Soc. 4525-4532, 1960.

Ashley et al. teaches disubstituted triazines, which include compounds claimed in the instant claim. See compound shown on page 4530, second paragraph.

This rejection is same as made in the previous office action.

Application/Control Number: 10/649,017

Art Unit: 1624

Applicants' argument seems to indicate that the said claims were amended to obviate this rejection. However, claims 14 and 16 as presented do not show any such amendment.

Hence, this rejection is maintained.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 14-20 and 23-24 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-11 of U.S. Patent No. 6,638,932. Although the conflicting claims are not identical, they are not patentably distinct from each other because the subject matter embraced in the instant claims overlap with the subject matter embraced in the US patent 6,638,932. Note the instant genus of formula I, its composition and method of use to treat HIV, is also generically claimed in the US patent 6,638,932.

Application/Control Number: 10/649,017

Art Unit: 1624

This rejection is same as made in the previous office action except that cancelled

claim 21 is excluded and newly added claims 23-24 are included in this rejection.

Applicants' argument to overcome this rejection is deemed as not persuasive.

First of all, applicants have not shown that instant claims are not obvious over

claims of US 6,638,932. The traversal appears to argue the withdrawal made to newly

added claims as not originally presented in parent application.

Secondly, the claims withdrawn in the parent application were not originally

presented but afterwards which would require additional search as they had core

compounds, which were not searched. Whereas, the parent application 09/831,808, the

aminotriazine core can be appended to variable core at any position available and the

variables a¹, a², a³ and a⁴ in contiguous position while in the instant claims they are not.

Instant claims requires b¹, b² and b³, b⁴ be not contiguous and must have at the position

to the attachment of aminotriazine, a cyano substituent. Although there are some

overlaps, these claims presented new genus of compounds and were withdrawn in the

parent application. Applicants had not traversed the same.

Hence, this rejection is deemed as proper and is maintained.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time

policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE

MONTHS from the mailing date of this action. In the event a first reply is filed within

TWO MONTHS of the mailing date of this final action and the advisory action is not

Page 5

Application/Control Number: 10/649,017

Art Unit: 1624

mailed until after the end of the THREE-MONTH shortened statutory period, then the

shortened statutory period will expire on the date the advisory action is mailed, and any

extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

the advisory action. In no event, however, will the statutory period for reply expire later

than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication from the examiner should be

addressed to Venkataraman Balasubramanian (Bala) whose telephone number is (571)

272-0662. The examiner can normally be reached on Monday through Thursday from

8.00 AM to 6.00 PM. The Supervisory Patent Examiner (SPE) of the art unit 1624 is

Mukund Shah whose telephone number is (571) 272-0674. If Applicants are unable to

reach Mukund Shah within 24-hour period, they may contact James O. Wilson, Acting-

SPE of art unit 1624 at 571-272-0661.

The fax phone number for the organization where this application or proceeding

is assigned (703) 872-9306. Any inquiry of a general nature or relating to the status of

this application or proceeding should be directed to the receptionist whose telephone

number is (571) 272-1600.

Veukataraman Balasukanah Venkataraman Balasubramanian

2/21/2005